ADXNAddex Therapeutics Ltd.

Nasdaq addextherapeutics.com


$ 9.79 $ -0.57 (-5.58 %)    

Friday, 13-Sep-2024 12:24:22 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 9.64
$ 10.01
-- x --
-- x --
$ 9.60 - $ 10.01
$ 5.00 - $ 27.90
45,399
na
201.15M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-addex-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Addex Therapeutics (NASDAQ:ADXN) with a Buy and maintains $30 ...

 johnson-johnson-partner-addex-therapeutics-selects-investigational-compound-for-substance-use-disorder

Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatmen...

Core News & Articles

TRIB: 105% | Trinity Biotech shares are trading higher after the company announced an increase in projected revenue for its Tri...

 addex-and-indivior-choose-clinical-candidates-from-their-gabab-positive-allosteric-modulator-research-partnership

Under the terms of the agreement, Addex is eligible for payment of up to USD 330 million on successful achievement of prespecif...

 hc-wainwright--co-upgrades-addex-therapeutics-to-buy-announces-30-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Addex Therapeutics (NASDAQ:ADXN) from Neutral to Buy and announc...

 after-disappointing-data-johnson--johnson-halts-developing-epilepsy-drug-candidate

Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epileps...

 addex-partner-janssen-discontinues-adx71149-epilepsy-treatment-after-phase-2-study

The decision follows top-line Phase 2 data announced on April 29, 2024, showing that adjunctive ADX71149 (JNJ-40411813) adminis...

 addex-presents-results-from-gabab-pam-cough-program-at-the-thirteenth-london-international-cough-symposium

"To our knowledge, this is the first time a highly selective GABAB PAM has demonstrated antitussive activity in animal mode...

 addex-therapeutics-q1-eps-137-up-from-520-yoy-sales-26883k-down-from-54243k-yoy

Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.37) per share. This is a 73.69 percent increase over losses o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION